A5085058149- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Glioma Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Head and Neck Cancer Studies
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Cancer Cells and Metastasis
- Health Systems, Economic Evaluations, Quality of Life
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Head and Neck Surgical Oncology
Instituto de Investigación Marqués de Valdecilla
2019-2025
Marqués de Valdecilla University Hospital
2015-2024
CancerCare Manitoba
2008-2023
Memorial Sloan Kettering Cancer Center
2008-2023
Novocure (United States)
2023
Fundación Marques de Valdecilla
2013-2018
Grand Charleroi Hospital
2014
Genentech
2013
Universidad de Sevilla
2013
Hospital Universitario Virgen del Rocío
2013
Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated efficacy cetuximab plus platinum-based chemotherapy as first-line treatment patients with neck.We randomly assigned 220 442 eligible untreated neck to receive cisplatin (at a dose 100 mg per square meter body-surface area on day 1) carboplatin an under curve 5 milliliter minute, 1-hour intravenous infusion fluorouracil 1000 for 4 days) every 3 weeks maximum 6...
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 as compared with chemotherapy first-line therapy for MSI-H–dMMR advanced metastatic colorectal cancer is unknown.
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating RAS may also be negative predictive biomarkers for anti-EGFR
Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as monotherapy for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). The Panitumumab Randomized Trial in Combination With Chemotherapy Metastatic Colorectal Cancer to Determine Efficacy (PRIME) was designed evaluate the efficacy and safety of panitumumab plus infusional fluorouracil, leucovorin, oxaliplatin (FOLFOX4)...
Purpose To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). Patients Methods The initial design of this trial was a randomized, two-arm, noninferiority, phase III comparison XELOX versus FOLFOX-4. After patient accrual had begun, the amended 2003 after bevacizumab data became available. resulting 2 × factorial randomly assigned patients FOLFOX-4, then also receive...
In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is standard first-line regimen. The cumulative neurotoxicity often requires therapy to be stopped in patients who are still responding. This study evaluates new strategy intermittent treatment that based on FOLFOX7, simplified regimen high-dose oxaliplatin.Previously untreated were randomly assigned either FOLFOX4 administered every 2 weeks until progression (arm A) or FOLFOX7...
To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab mFOLFOX6 in patients with previously untreated wild-type (WT) KRAS exon 2 (codons 12 13) metastatic colorectal cancer (mCRC). A prespecified secondary objective was to assess treatment effects an extended RAS analysis that included exons 2, 3, 4 of NRAS.Patients WT tumors were randomly assigned at a one-to-one ratio mFOLFOX6. The primary end point progression-free survival (PFS); points...
BackgroundThe Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) demonstrated that panitumumab–FOLFOX4 significantly improved progression-free survival (PFS) versus FOLFOX4 as first-line treatment of wild-type (WT) KRAS metastatic (mCRC), the primary end point study.Patients and methodsPatients were randomized 1:1 panitumumab 6.0 mg/kg every 2 weeks + (arm 1) or 2). This prespecified final descriptive analysis efficacy...
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard care chemotherapy ± bevacizumab or cetuximab (chemo) as first-line therapy for patients (pts) with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). We present results final PFS analysis. Methods: A total 307 pts MSI-H/dMMR mCRC determined locally ECOG PS 0 1 were randomly...
The aim of this phase III trial was to compare the efficacy and safety capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC).A total 348 patients were randomly assigned receive XELOX (oral 1,000 mg/m2 bid 14 days 130 on day 1 every 3 weeks) or FUOX (continuous-infusion FU 2,250 during 48 hours 1, 8, 15, 22, 29, 36 85 29 6 weeks).There no significant differences...
Abstract Purpose. The aim of this phase III trial was to compare the efficacy and safety bevacizumab alone with those capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy XELOX in first-line patients metastatic colorectal cancer (mCRC). Patients Methods. were randomly assigned receive six cycles bevacizumab, capecitabine, every 3 weeks followed by or until progression. primary endpoint progression-free survival (PFS) interval; secondary endpoints...
Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety and tolerability of cetuximab in first-line treatment recurrent/metastatic squamous cell carcinoma head neck (SCCHN). Patients Methods Treatment comprised (initial dose 400 mg/m 2 with subsequent weekly doses 250 ) combination 3-week cycles either cisplatin (100 or carboplatin (area under curve, 5), each a 5-day infusion fluorouracil (FU) at escalating 600, 800, 1,000 /d. The divided into two...
Abstract The great majority of thyroid cancers are the non-medullary type. Here we report findings from a genome-wide association study cancer, including in total 3,001 patients and 287,550 controls five groups European descent. Our results yield novel loci (all with P combined <3 × 10 −8 ): 1q42.2 (rs12129938 PCNXL2 ), 3q26.2 (rs6793295 missense mutation LRCC34 near TERC 5q22.1 (rs73227498 between NREP EPB41L4A 10q24.33 (rs7902587 OBFC1 two independently associated variants at 15q22.33...
To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780). Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizumab. The primary endpoint was PFS; secondary endpoints included OS, objective response rate, duration of (DoR), time response, resection safety. Treatment effect by tumour RAS status a prespecified objective....
3500 Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free survival (PFS) at second interim analysis (IA2) in patients (pts) with MSI-H/dMMR mCRC. The continued to final of overall (OS), planned after 190 OS events or 12 months IA2, whichever occurred first. We present results OS, IA2. Methods: A total 307 pts mCRC and ECOG PS 0 1 were 1:1 pembro 200 mg Q3W for up 2y...